Professor Albert Chan Chi-yan (left) and Dr Chiang Chi-leung collaborate once more to develop the innovative ‘cocktail’ strategy—Locoregional therapy and immunotherapy (LRT-IO) approach. This method features three treatment stages: stereotactic beam radiotherapy (SBRT) with optional transarterial chemoembolisation (TACE), followed by immunotherapy (IO). 陳智仁教授（左）和蔣子樑醫生合作無間，再度攜手研發創新「雞尾酒」策略——局部與免疫治療聯合療法（LRT-IO）。方案包括三種治療：立體定向放射治療（SBRT）與非必要的肝動脈化療栓塞術（TACE），及後續的免疫治療（IO )。The LRT-IO approach is a potentially curative treatment for large, unresectable liver cancer, with a 46% complete response rate, and a 75% survival rate among patients who achieved a complete response. The photo shows Professor Albert Chan Chi-yan (left) and Dr Chiang Chi-leung. 局部和免疫治療聯合療法方案對體積較大、無法進行手術切除的肝癌具有根治潛力，其完全緩解率達到46%，而獲完全緩解患者的存活率更高達75%。圖為陳智仁教授（左）和蔣子樑醫生。
